Skip to main content

For Industry

You are here

UM Ventures, Baltimore Life Sciences IP Fund

Accelerating Technology Commercialization
at University of Maryland, Baltimore

Established in February 2018, the UM Ventures, Baltimore Life Sciences IP Fund (LSIPF) provides direct support to commercially promising translational research projects. LSIPF investments are directed towards generating third-party data that strengthens and expands the intellectual property of our inventor’s technologies.

  • 15


  • 19

    Medical Devices

  • 34

    Total Investments

  • $4

    Committed or Invested
  • $19.8M

    Catalyzed Capital

    18:1 ratio

  • 31

    Research Outcomes

  • 26

    Commercial Outcomes

  • 57

    Total Outcomes

Successful Startups


Gen1E Lifesciences

Gen1E Lifesciences is developing a clinical-stage AI platform to accelerating first-in-class immunomodulators for rare and inflammatory diseases.


Isoprene Pharmaceuticals

Isoprene Pharmaceuticals is developing small molecules for oncology and dermatology applications. They were awarded a $2M Phase II SBIR grant from the National Cancer Institute and have received investment from a strategic partner.


Protaryx Medical

Protaryx Medical is developing a device for use during beating heart cardiology procedures. They have $8.3M to-date, and their Series A funding round was led by Silicon Valley-based Ajax Health.

Eligibility Requirements

  • Technologies must be disclosed to UMB to qualify.
  • All technology types (biologic, small molecule, software, diagnostic, device) are considered.


  • To learn more about the LSIPF or to discuss possible projects, please reach out to Mark Lafferty.